Randomized phase II study to investigate the efficacy, safety and tolerability of ZK 230211 (25 mg vs. 100 mg) as second-line endocrine therapy for postmenopausal women with hormonereceptor-positive metastatic breast cancer

Project

Randomized phase II study to investigate the efficacy, safety and tolerability of ZK 230211 (25 mg vs. 100 mg) as second-line endocrine therapy for postmenopausal women with hormonereceptor-positive metastatic breast cancer

Completed · 2008 until 2009

Ruhstaller Thomas, Räss Andrea

Type

Clinical Studies

Range

Multicentric, KSSG as participating partner

Units

Brustzentrum St.Gallen, Endokrinologie | Diabetologie | Osteologie | Stoffwechselerkrankungen

Status

Completed

Start Date

2008

End Date

2009

Financing

Industry

Study Design

Prospective, randomized, open-label, parallel group, multi-center

Keywords

hormone receptor-positive tumors, breast cancer

Partner

Prof. Walter Jonat, Kiel, Klinik für Gynäkologie und Geburtshilfe Dr. Iris Kuss Bayer Schering Pharma AG, Study Team Lead, Dr. Michael, Bayer Schering Pharma AG, Dr. Kretschmann Bayer Schering Pharma AG

Brief description/objective

Breast cancer is the second leading cause of cancer-related death in women today (after lung cancer) and is the most common cancer among women worldwide. According to the World Health Organization (WHO), more than 1.2 million people will be diagnosed with breast cancer worldwide in 2005 (Imaginis 2005).
The risk of developing breast cancer increases with age with about two thirds of breast cancers occurring in postmenopausal women. Endocrine therapy is the most important systemic treatment for patients with hormone receptor-positive tumors, which account for two thirds of
breast cancers.